AMARIN CORP PLC\UK Restructuring Costs
AMARIN CORP PLC\UK (AMRN) reported Restructuring Costs of $40.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2026-07-29
- AMARIN CORP PLC\UK restructuring costs for the quarter ending 2026-06-30 was $40.00K, a 99.80% decline year-over-year.
- AMARIN CORP PLC\UK restructuring costs for the quarter ending 2026-03-31 was $3.29M.
- AMARIN CORP PLC\UK restructuring costs for the quarter ending 2025-09-30 was $9.80M.
- AMARIN CORP PLC\UK restructuring costs for the quarter ending 2025-06-30 was $20.18M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month |
|---|---|---|---|
| 2026-06-30 | $40.00K 10-Q · filed 2026-07-29 | $3.33M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $3.29M 10-Q · filed 2026-04-29 | ||
| 2025-09-30 | $9.80M 10-Q · filed 2025-10-29 | $29.99M derived: sum of 2 quarters · filed 2026-07-29 | $29.99M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $20.18M 10-Q · filed 2026-07-29 | $20.18M 10-Q · filed 2026-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |